# GLP-1 Side Effects Timeline: Week by Week, How Long They Last and When to Call

> Most GLP-1 side effects are digestive and cluster in the first weeks and after each dose increase. In pooled semaglutide trials, a nausea episode lasted a median of 8 days, diarrhea 3 days and vomiting 2 days, while constipation lasted a median of 47 days. First-time stomach symptoms leveled off after about week 20. Severe belly pain that will not go away needs prompt medical care.

- URL: https://glpcalendar.app/blog/glp-1-side-effects-timeline
- Published: 2026-09-29
- Updated: 2026-09-29
- Publisher: GLP Calendar (https://glpcalendar.app)

GLP-1 medications such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound) and orforglipron (Foundayo) cause side effects that follow a predictable timeline. Most are digestive, mild to moderate and tied to dose increases. This guide uses the US labels and trial analyses to show what is common, how long it lasts and when to call your doctor.

## What are the most common GLP-1 side effects?

The most common GLP-1 side effects are digestive: nausea, diarrhea, vomiting and constipation. In the weight-management trials behind the US labels, 56% to 73% of people on the medicine reported at least one stomach or bowel side effect, compared with 30% to 47% on placebo. Most cases were mild to moderate.

| Side effect | Wegovy 2.4 mg | Zepbound 5 to 15 mg | Foundayo 5.5 to 17.2 mg |
|---|---|---|---|
| Any digestive side effect | 73% vs 47% | 56% vs 30% | 60–69% vs 37% |
| Nausea | 44% vs 16% | 25–29% vs 8% | 26–35% vs 10% |
| Diarrhea | 30% vs 16% | 19–23% vs 8% | 21–25% vs 11% |
| Vomiting | 24% vs 6% | 8–13% vs 2% | 13–24% vs 4% |
| Constipation | 24% vs 11% | 11–17% vs 5% | 20–27% vs 9% |
| Hair loss | 3% vs 1% | 4–5% vs 1% | 4–5% vs 2% |

Figures are drug vs placebo from each label's pooled trials of up to 68 to 72 weeks; ranges span the doses tested. The labels warn that rates from different trials cannot be compared directly. Ozempic, which uses lower semaglutide doses for type 2 diabetes, lists nausea in **15.8%** (0.5 mg) and **20.3%** (1 mg) of patients vs 6.1% on placebo.

### Skin sensations and hair loss

The 7.2 mg Wegovy dose (Wegovy HD, FDA-approved March 19, 2026) adds dysesthesia: tingling, burning or painful skin, reported by **22%** on 7.2 mg vs 6% on 2.4 mg and 0% on placebo. The FDA said it generally resolved on its own or with a dose reduction. Nausea (39% vs 35% vs 13%) and vomiting (22% vs 16% vs 6%) were also higher at 7.2 mg.

Hair loss, which each label links to weight reduction, is far more common in women: 7.1% vs 0.5% of men on Zepbound, 7% vs 0.9% on Foundayo and 8.4% vs 0.2% on Wegovy 7.2 mg. The 2025 joint nutrition advisory lists excessive hair loss as a possible sign of nutrient deficiency, so mention it to your clinician.

## How long does GLP-1 nausea last?

Usually days, not weeks. In a pooled analysis of the STEP 1–3 trials of semaglutide 2.4 mg (Wegovy), the median nausea episode lasted 8 days, diarrhea 3 days and vomiting 2 days, similar to episodes on placebo. Constipation lasted longer, with a median of 47 days on semaglutide vs 35 days on placebo.

| Symptom | Median episode on semaglutide 2.4 mg | On placebo |
|---|---|---|
| Nausea | 8 days | Similar |
| Diarrhea | 3 days | Similar |
| Vomiting | 2 days | Similar |
| Constipation | 47 days | 35 days |

The data come from Wharton and colleagues (2022), who pooled 3,379 participants. People can have more than one episode, and a small share kept having symptoms throughout treatment. We did not find comparable published episode lengths for tirzepatide; the Zepbound label says most nausea, vomiting and diarrhea happened during dose escalation and decreased over time.

## When do GLP-1 side effects go away?

For most people, digestive side effects tend to fade once the dose is stable. In the semaglutide trials, the number of people having their first stomach side effect leveled off after about week 20, and nausea, diarrhea and vomiting peaked around week 20 before declining. The tirzepatide and orforglipron labels describe the same pattern.

Week 20 is not a magic date: in those trials the full 2.4 mg dose was reached at week 16, so the peak came shortly after the last step up. Constipation behaved differently, plateauing at about week 10. The Zepbound label adds that most people who stopped because of side effects did so in the first few months, and that tirzepatide's slowing of stomach emptying is largest after the first dose.

## GLP-1 side effects week by week

The timeline follows your dose schedule more than the calendar. Symptoms tend to cluster in the first weeks on the starting dose and in the weeks after each increase, some people notice them most in the days right after a weekly shot, and they usually ease once the dose stays the same.

| Phase | Wegovy injection | Zepbound | Foundayo |
|---|---|---|---|
| Starting dose | 0.25 mg, weeks 1–4 | 2.5 mg, weeks 1–4 | 0.8 mg, at least 30 days |
| Step-ups | Every 4 weeks | 2.5 mg steps, at least 4 weeks apart | At least 30 days apart |
| Highest dose, at the earliest | 2.4 mg from week 17; 7.2 mg from week 21 | 15 mg from week 21 | 17.2 mg after about 5 months |

These are label minimums, not targets; your prescriber sets the pace.

### Weeks 1 to 4: the starting dose

Starting doses let your body adjust; the Zepbound label says 2.5 mg is not a maintenance dose. Nausea, fullness and appetite changes often begin now. Because tirzepatide slows stomach emptying, its label tells people on birth control pills to switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase (Foundayo: 30 days).

### The first days after each weekly shot

Blood levels peak 1 to 3 days after a semaglutide injection and about 24 hours (range 8 to 72 hours) after a tirzepatide injection. Some people notice fullness or nausea most in that window. This is plausible but not well studied, so your own log is the best guide.

### After each dose increase

Each step up can bring a new round of symptoms. After a weekly dose change, blood levels take about 4 weeks (tirzepatide) to 4 to 5 weeks (semaglutide) to settle. If a step is hard to tolerate, tell your prescriber: the Wegovy label allows the next increase to be delayed by 4 weeks, and the Zepbound label allows a lower maintenance dose.

### Maintenance

On a stable dose, most people have fewer and milder episodes. In STEP 4, only two people who had tolerated 20 weeks of semaglutide later stopped for digestive reasons. Breaks can reset the clock: the current Wegovy label says escalation should restart at a lower dose after 2 or more missed weekly doses in a row, and the Foundayo label says the same after 7 or more missed daily doses. See our guide to [missed GLP-1 doses](https://glpcalendar.app/blog/missed-glp-1-dose).

## Does no nausea mean your GLP-1 isn't working?

No. In the semaglutide STEP 1–3 trials, people without digestive side effects lost about as much weight as people with them, and less than 1 percentage point of the extra weight loss was explained by those side effects. A tirzepatide analysis found nausea, vomiting, diarrhea and indigestion accounted for at most about 3% of weight reduction.

Average semaglutide weight loss ranged from 9.6% to 17.1% across the three trials in people without digestive side effects and from 11.4% to 17.7% in people with them. These are trial averages from analyses written with the manufacturers' scientists, and individual results vary. Severe symptoms are not a sign the medicine is working better; they are a reason to call your prescriber.

## How can you ease GLP-1 nausea and constipation?

Guidelines suggest smaller, more frequent meals, stopping when comfortably full, going easy on fatty, greasy or spicy food while doses rise, limiting alcohol and fizzy drinks, and drinking enough fluids. They come from the 2025 joint nutrition advisory, a 2025 expert consensus and the labels, and do not replace your prescriber's advice.

1. **Eat smaller, more frequent meals**, and avoid fatty or high-fiber foods in the first few days of treatment (joint advisory).
2. **Avoid long gaps without food.** Nausea often appears in the morning or after long periods without eating; the advisory suggests breakfast, then small meals every 3 to 4 hours with fluids.
3. **Stop when comfortably full**, and don't eat when you aren't hungry (expert consensus).
4. **Limit high-fat, greasy and spicy food, alcohol and fizzy drinks**, especially while your dose is rising.
5. **Keep drinking fluids.** The Medication Guides say this helps reduce the chance of dehydration.
6. **For constipation, pair fluids with fiber from food.** If that is not enough, ask your pharmacist or prescriber about next steps, including anti-nausea or laxative options.

See also our guide to [protein, fiber and water on a GLP-1](https://glpcalendar.app/blog/glp-1-protein-fiber-water). A tracker such as GLP Calendar can log side-effect check-ins next to each dose, which makes a pattern easier to show your prescriber.

## When should you call a doctor about GLP-1 side effects?

Call promptly, or get emergency care, for the warning signs in the Medication Guides: severe stomach pain that won't go away, signs of gallbladder trouble, vomiting or diarrhea that won't stop, an allergic reaction, low blood sugar, vision changes, a racing heart at rest, or a lump in the neck.

### Stop and get help right away

- **Serious allergic reaction:** swelling of the face, lips, tongue or throat; trouble breathing or swallowing; severe rash or itching; fainting or dizziness; a very rapid heartbeat. The Medication Guides say to stop the medicine and get medical help right away.
- **Severe stomach pain that will not go away**, with or without vomiting, sometimes felt from the abdomen through to the back. This can signal pancreatitis; the Medication Guides say to stop the medicine and call your healthcare provider right away.
- **Severe dehydration:** confusion, fainting, not urinating, or a rapid heartbeat or breathing (MedlinePlus).
- **Too much medicine:** an overdose can cause severe nausea, vomiting and low blood sugar. Call your healthcare provider or Poison Help at **1-800-222-1222**, or go to the nearest emergency room.

### Call your prescriber promptly

- **Gallbladder signs:** upper stomach pain, fever, yellowing of the skin or eyes, or clay-colored stools.
- **Nausea, vomiting or diarrhea that does not go away**, or signs of dehydration such as strong thirst, dry mouth, dark urine, urinating less or dizziness. The labels warn that fluid loss can lead to kidney problems.
- **Low blood sugar** if you also take insulin or a sulfonylurea: shakiness, sweating, dizziness, blurred vision, hunger, confusion or a fast heartbeat.
- **Changes in vision** if you have type 2 diabetes.
- **A racing or pounding heart** that lasts several minutes (Wegovy Medication Guide).
- **A lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath**, which the labels list as possible thyroid tumor symptoms.
- **New or worsening depression, suicidal thoughts or unusual mood changes.** In a crisis, call or text 988.

Planning surgery? Tell every clinician involved that you take a GLP-1; our [half-life guide](https://glpcalendar.app/blog/glp-1-half-life) explains why timing matters. You can report side effects to the FDA at 1-800-FDA-1088.

## What changed in GLP-1 side-effect labeling in 2026?

Two US changes matter most. In January 2026 the FDA asked for the suicidal-behavior warning to be removed from the Wegovy, Zepbound and Saxenda labels, and by June 2026 the Wegovy label had changed its restart advice after missed doses. In the EU, semaglutide labels list the eye condition NAION.

- **Suicidality warning removed.** On January 13, 2026, the FDA requested the removal after a review of 91 placebo-controlled trials (107,910 patients) and a Sentinel study of more than 2.2 million users found no increased risk. The Wegovy and Saxenda labels mark the section removed in 02/2026. The FDA still asks patients to report new or worsening depression, suicidal thoughts or unusual mood changes.
- **Restarting after missed doses.** The March 2026 Wegovy label said that after 2 or more missed doses, dosing could resume as scheduled or restart escalation if needed; the June 2026 label says escalation should restart at a lower dose.
- **NAION in the EU, not the US label.** On June 6, 2025, the European Medicines Agency's safety committee concluded that non-arteritic anterior ischemic optic neuropathy (NAION), optic nerve damage that can cause vision loss, is a very rare side effect of semaglutide, affecting up to 1 in 10,000 people. As of September 2026, the US labels for Ozempic, Wegovy and Rybelsus do not list it. EMA advises contacting a doctor without delay about sudden vision loss or rapidly worsening eyesight.

## What to do next

1. Expect digestive symptoms mainly in the first months and after each step up. Most episodes last days; constipation can last weeks.
2. Log the date, dose, symptoms and severity, especially in the 4 weeks after a dose increase, and bring the log to your prescriber.
3. Don't judge the medicine by how sick you feel.
4. Learn the red flags above and save Poison Help (1-800-222-1222) in your phone.
5. For drug details, read our [semaglutide](https://glpcalendar.app/blog/semaglutide) and [tirzepatide](https://glpcalendar.app/blog/tirzepatide) guides.

## Frequently asked questions

### Does Ozempic nausea go away?

For most people it does. The duration data come from trials of Wegovy 2.4 mg, which contains the same medicine as Ozempic: a typical nausea episode lasted about 8 days, and nausea became less common after the full dose was reached. A small share of people keep having symptoms, which is worth raising with your prescriber.

### Is it normal to feel worse after a dose increase?

Yes, it is common. The Wegovy, Ozempic, Zepbound and Foundayo labels all report digestive side effects most often during dose escalation. If a new dose is hard to tolerate, tell your prescriber; the Wegovy label, for example, allows the next increase to be delayed by 4 weeks.

### Why do women report more hair loss on tirzepatide?

In the Zepbound trials, hair loss was reported by 7.1% of women and 0.5% of men, and the label says it was associated with weight reduction. The label does not explain the difference. The 2025 joint nutrition advisory lists excessive hair loss as a possible sign of nutrient deficiency, so mention it to your clinician.

### Can I take anti-nausea medicine with a GLP-1?

Ask your prescriber. The 2025 joint nutrition advisory notes that anti-nausea medicines can help while people adjust to treatment and during dose increases, but which medicine, if any, is a prescription decision.

### Should I stop my GLP-1 if I have side effects?

Do not stop or change a dose on your own for ordinary side effects; talk to your prescriber. The Medication Guides do say to stop the medicine and get help right away for signs of a serious allergic reaction, and to stop and call your provider for severe stomach pain that will not go away.

## Sources

- [Wegovy (semaglutide) US prescribing information and Medication Guide, rev. 06/2026, DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
- [Zepbound (tirzepatide) US prescribing information and Medication Guide, rev. 08/2026, DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
- [Foundayo (orforglipron) US prescribing information, rev. 07/2026, DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62)
- [Ozempic (semaglutide) US prescribing information, rev. 06/2026, DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79)
- [Wharton et al. GI tolerability of semaglutide 2.4 mg in STEP 1-4, Diabetes, Obesity and Metabolism, 2022](https://pmc.ncbi.nlm.nih.gov/articles/PMC9293236/)
- [Rubino et al. GI tolerability and weight reduction with tirzepatide in SURMOUNT-1 to -4, Diabetes, Obesity and Metabolism, 2025](https://pubmed.ncbi.nlm.nih.gov/39789843/)
- [Mozaffarian et al. Nutritional priorities to support GLP-1 therapy: joint advisory from ACLM, ASN, OMA and TOS, Obesity Pillars, 2025](https://pmc.ncbi.nlm.nih.gov/articles/PMC12264624/)
- [Sievenpiper et al. Nutritional and lifestyle care with GLP-1-based therapies: Delphi expert consensus, Obesity Pillars, 2025 (funded by Nestle Health Science)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12768930/)
- [FDA Drug Safety Communication: FDA requests removal of suicidal behavior and ideation warning from GLP-1 RA labels, January 13, 2026](https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp)
- [FDA press release: FDA approves higher-dose semaglutide (Wegovy HD 7.2 mg), March 19, 2026](https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide)
- [European Medicines Agency: PRAC concludes NAION is a very rare side effect of semaglutide medicines, June 6, 2025](https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy)
- [MedlinePlus (US National Library of Medicine): Dehydration](https://medlineplus.gov/dehydration.html)

---

Educational content, not medical advice. GLP Calendar is a tracking app; it does not recommend or calculate doses.